Friboulet's study also supported the evidence that the ERCC1-202 isoform is the sole one endowed with ERCC1 activity in DNA repair pathways and might support as an accurate predictor of cisplatin benefit in patients with NSCLC [45]. Here, ERCC1 is linked to non-small cell lung carcinoma.